Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni LV, et al
Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,318 followers
Timothy Garvey, MD, FACE Professor of Medicine University of Alabama at Birmingham Disclosures: Garvey reports conducting clinical trials funded by his institution for Eli Lilly, Epitomee, Novo Nordisk and Pfizer and serving as a volunteer on advisory board without receipt of financial compensation for Eli Lilly, Novo Nordisk, JAZZ Pharmaceuticals and Boehringer Ingelheim
Until those pieces line up, cost often falls more heavily on the patient
Recent concerns have emerged about whether Mounjaro causes suicidal thoughts, prompting regulatory reviews by the MHRA and EMA
Some patients achieve their goal weight in 1218 months and then remain on a lower maintenance dose indefinitely
US$ 25.67
US$ 21.86
US$ 20.21
US$ 25.92
US$ 25.85
US$ 27.05
